Arjan A van de Loosdrecht

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. ncbi request reprint Cutting edge: flow cytometry in myelodysplastic syndromes
    Arjan A van de Loosdrecht
    Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    J Natl Compr Canc Netw 11:892-902. 2013
  2. doi request reprint Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Leuk Lymphoma 54:472-5. 2013
  3. pmc Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Haematologica 94:1124-34. 2009
  4. ncbi request reprint Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry
    Arjan A van de Loosdrecht
    Department of Hematology, Vrije Universiteit VU University Medical Center, VU Institute for Cancer and Immunology, Amsterdam, The Netherlands
    Blood 111:1067-77. 2008
  5. ncbi request reprint The dendritic cell: the piano player in orchestrating the immune response in leukemia
    Arjan A van de Loosdrecht
    Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    Leuk Lymphoma 48:217-8. 2007
  6. ncbi request reprint Emerging immunobiological concepts in macrophage and dendritic cell research and clinical implications
    Arjan A van de Loosdrecht
    Department of Hematology, VU Institute of Cancer and Immunology V ICI, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands
    Immunobiology 211:403-6. 2006
  7. ncbi request reprint Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Curr Opin Hematol 11:419-25. 2004
  8. ncbi request reprint Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Anticancer Drugs 15:189-201. 2004
  9. ncbi request reprint Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation
    Ilse Houtenbos
    Department of Haematology BR 250, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Cancer Immunol Immunother 52:455-62. 2003
  10. pmc Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation
    Willemijn van den Ancker
    Department of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Cancer Immunol Immunother 60:37-47. 2011

Detail Information

Publications60

  1. ncbi request reprint Cutting edge: flow cytometry in myelodysplastic syndromes
    Arjan A van de Loosdrecht
    Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    J Natl Compr Canc Netw 11:892-902. 2013
    ..This article highlights tools to implement FC in the diagnostic workup of MDS. Current advances in FC for diagnosis and prognosis of MDS are also introduced. ..
  2. doi request reprint Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Leuk Lymphoma 54:472-5. 2013
    ..In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS...
  3. pmc Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Haematologica 94:1124-34. 2009
    ..Standardization of FCM in myelodysplastic syndromes may thus contribute to improved diagnosis and prognostication of myelodysplastic syndromes in the future...
  4. ncbi request reprint Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry
    Arjan A van de Loosdrecht
    Department of Hematology, Vrije Universiteit VU University Medical Center, VU Institute for Cancer and Immunology, Amsterdam, The Netherlands
    Blood 111:1067-77. 2008
    ....
  5. ncbi request reprint The dendritic cell: the piano player in orchestrating the immune response in leukemia
    Arjan A van de Loosdrecht
    Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    Leuk Lymphoma 48:217-8. 2007
  6. ncbi request reprint Emerging immunobiological concepts in macrophage and dendritic cell research and clinical implications
    Arjan A van de Loosdrecht
    Department of Hematology, VU Institute of Cancer and Immunology V ICI, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands
    Immunobiology 211:403-6. 2006
  7. ncbi request reprint Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Curr Opin Hematol 11:419-25. 2004
    ....
  8. ncbi request reprint Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications
    Arjan A van de Loosdrecht
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Anticancer Drugs 15:189-201. 2004
    ..An update is provided on the use of Ab-targeted therapies in clinical trials with emphasis on new emerging strategies to further expand the successful field of immunotherapy in leukemia and lymphoma...
  9. ncbi request reprint Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation
    Ilse Houtenbos
    Department of Haematology BR 250, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Cancer Immunol Immunother 52:455-62. 2003
    ..For clinical purposes it is desirable to culture APCs under serum-free conditions. Therefore, we compared morphological, immunophenotypical and functional outcome of the serum-free culture of AML-APCs to their serum-enriched culture...
  10. pmc Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation
    Willemijn van den Ancker
    Department of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Cancer Immunol Immunother 60:37-47. 2011
    ..Taken together, our data demonstrate that even though R848 improved uptake of apoptotic leukemic cells, the sequential use of R848 and CC is counter-indicated due to its adverse effects on MoDC maturation...
  11. doi request reprint The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity
    Ilse Houtenbos
    Department of Haematology, VU University Medical Centre, Amsterdam, The Netherlands
    Br J Haematol 142:273-83. 2008
    ..We propose that the alphaCD40/alphaCD28-bispecific diabody can serve as a potent therapeutic tool to effectively augment anti-tumour T-cell responses elicited by AML-DC...
  12. ncbi request reprint Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines
    Jurjen M Ruben
    Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Cancer Immunol Immunother 63:335-45. 2014
    ....
  13. doi request reprint Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia
    Marvin M van Luijn
    Department of Hematology, VU Institute for Cancer and Immunology, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Immunotherapy 2:85-97. 2010
    ....
  14. pmc Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes
    Marvin M van Luijn
    Department of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Cancer Immunol Immunother 59:1825-38. 2010
    ....
  15. doi request reprint Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells
    Marvin M van Luijn
    Department of Hematology, Cancer Center Amsterdam and VU Institute for Cancer and Immunology, VU University Medical Center, The Netherlands
    Cancer Res 71:2507-17. 2011
    ..Our findings offer a clinical rationale to downmodulate CLIP on leukemic blasts as a strategy to degrade immune escape and improve leukemia-specific T-cell immunity in AML patients...
  16. doi request reprint Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells
    Theresia M Westers
    Department of Hematology, Cancer Center Amsterdam VUmc Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    Immunotherapy 3:569-76. 2011
    ..Our data show the potency of dendritic cell-based vaccination strategies for the induction of T cell-mediated responses to eradicate minimal residual disease...
  17. doi request reprint MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia
    David C de Leeuw
    Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands
    Clin Cancer Res 19:2187-96. 2013
    ..The lack of clear classification of acute leukemias of ambiguous lineage as either AML or ALL is a hurdle in treatment choice for these patients...
  18. pmc Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses
    Marvin M van Luijn
    Department of Hematology, VU Institute for Cancer and Immunology, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Haematologica 95:485-93. 2010
    ..The current study investigates the role of aberrant HLA class II antigen presentation on leukemic blasts by determining both the clinical and functional impact of the class II-associated invariant chain peptide (CLIP)...
  19. doi request reprint Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines
    Jurjen M Ruben
    Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands
    Immunotherapy 5:859-68. 2013
    ..Combined with advances in the design of apoptotic tumor-based vaccines, we are on the verge of creating an effective AML vaccine strategy, offering a much needed novel therapeutic option for this devastating disease. ..
  20. doi request reprint Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes
    Hetty J Bontkes
    Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands
    Leuk Res 36:921-30. 2012
    ..03) and in vivo (p < 0.006), indicating that Aza directly affects CD4(pos) polarization during activation in vitro. Upon in vivo treatment in high risk MDS patients, particularly the T(H)17-Treg axis is affected...
  21. doi request reprint Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment
    Theresia M Westers
    Department of Hematology, Vrije Universiteit VU University Medical Center, Amsterdam, The Netherlands
    Blood 115:1779-84. 2010
    ..In conclusion, FCM may add significantly to well-known predictive parameters in selecting MDS patients eligible for Epo/G-CSF treatment. This is of relevance regarding prevention of treatment failure...
  22. ncbi request reprint Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting
    Ilse Houtenbos
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 13:307-15. 2007
    ..Engagement of the costimulatory molecule 4-1BB can break immunologic tolerance and increase CTL responses. In this study, we examined the role of the 4-1BB ligand (4-1BBL) on T-cell responses induced by AML-DC...
  23. doi request reprint Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia
    Willemijn van den Ancker
    Department of Hematology, VU Institute for Cancer and Immunology, Cancer Center Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Immunotherapy 2:69-83. 2010
    ..This review discusses recent advances in DC research and the application of this knowledge towards new strategies for antigen loading of DCs in the treatment of minimal residual disease in acute myeloid leukemia...
  24. ncbi request reprint Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia
    Ilse Houtenbos
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Immunobiology 211:677-85. 2006
    ..Clinical relevant responses to DC-based immunotherapy are likely to only occur in non-end-stage patients. Application in early stage disease is mandatory to permit ultimate proof of clinical benefit of AML-DC vaccination strategy...
  25. ncbi request reprint High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia
    Willemijn van den Ancker
    Department of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    Leuk Res 38:691-3. 2014
    ..01-0.1% LAP(+) cells). Consequently, CLIP evaluation could be of additional value in the evaluation of MRD to predict a relapse of AML. ..
  26. ncbi request reprint Quantification of T-cell-mediated apoptosis in heterogeneous leukemia populations using four-color multiparameter flow cytometry
    Theresia M Westers
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Cytometry A 66:71-7. 2005
    ..This study supplies a flow cytometric method to analyze T-cell-mediated cytotoxic activity toward heterogeneous leukemic cell populations at a single-cell level...
  27. doi request reprint A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies
    Gert J Ossenkoppele
    Department of Haematology, VU University Medical Centre, Amsterdam, The Netherlands
    Br J Haematol 162:191-201. 2013
    ..The early signs of efficacy and absence of significant toxicity warrant further evaluation of tefinostat in larger studies. (clinicaltrials.gov identifier: NCT00820508)...
  28. doi request reprint Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy
    Nathalie Kerkhoff
    Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands
    Immunotherapy 5:621-37. 2013
    ..It has been suggested that impaired DC function can hamper adequate immune responses. This review focuses on the involvement of DCs in immune dysregulation in low- and high-risk MDS and the implications for DC-targeted therapies...
  29. ncbi request reprint A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin
    Willemijn van den Ancker
    Department of Hematology, Cancer Centre Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Cytometry B Clin Cytom 84:114-8. 2013
    ..Since the expression of solely cMPO can change the diagnosis from acute lymphoid leukemia into MPAL in the current WHO 2008, a consensus is needed for the cut-off for cMPO...
  30. pmc Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells
    Marvin M van Luijn
    Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    PLoS ONE 7:e34649. 2012
    ..The found participation of CLIP in the HLA-I antigen presentation pathway could reflect an aberrant mechanism in leukemic cells, but might also lead to elucidation of novel processing pathways or immune escape mechanisms...
  31. pmc Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia
    Marvin M van Luijn
    Department of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    Am J Pathol 179:2157-61. 2011
    ..Our findings show the additive value of CLIP analysis for a fast and unequivocal recognition of APL by flow cytometry in conjunction with morphology...
  32. doi request reprint Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy
    Shikhar Aggarwal
    Department of Haematology, VU Institute for Cancer and Immunology, VU University Medical Centre, Amsterdam, The Netherlands
    Br J Haematol 153:568-81. 2011
    ..This review is focused on the role of immune responses in MDS and the implications for the development of novel immune therapies...
  33. pmc Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome
    Martine E D Chamuleau
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Haematologica 94:496-506. 2009
    ..Immune activation could reflect undesired autoimmune reactions against normal hematopoietic precursor cells as well as effective immune-surveillance against dysplastic clones...
  34. ncbi request reprint Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia
    Theresia M Westers
    Department of Haematology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Biomed Pharmacother 61:306-14. 2007
    ..This review summarises data on active specific DC-based immunotherapy in acute and chronic myeloid leukaemia and discusses current optimisation strategies...
  35. doi request reprint Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival
    Yuri Souwer
    Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academical Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Br J Haematol 145:334-43. 2009
    ..Multivariate analysis revealed that the prognostic value of DOA mRNA was independent of the mutational status of the IGHV genes. Thus, aberrant transcription of DOA forms a novel and additional prognostic indicator for survival in B-CLL...
  36. ncbi request reprint Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy
    Willemijn van den Ancker
    Department of Hematology, VU University Medical Center, VU Institute for Cancer and Immunology, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Immunotherapy 5:1183-90. 2013
    ..Here, we demonstrate that AML cells can be expanded in vitro prior to differentiation with cocktails of cytokines with known myeloid growth-promoting effects...
  37. ncbi request reprint Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization
    Ilse Houtenbos
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Immunobiology 210:249-57. 2005
    ..This review discusses increased immunogenicity of AML blasts by differentiation into AML-DC and describes ways to augment the AML-DC vaccination approach...
  38. ncbi request reprint Monoclonal antibody therapy in haematological malignancies
    Martine E D Chamuleau
    Department of Haematology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Curr Clin Pharmacol 5:148-59. 2010
    ..Therefore, also some interesting phase III studies that are recruiting patients at this moment, and some new technical developments are discussed...
  39. ncbi request reprint Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome
    Martine E D Chamuleau
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Res 64:5546-50. 2004
    ..We hypothesize that DR+/CLIP- AML blasts are able to present leukemia-specific antigens to CD4+ T helper cells initiating an effective and long-lasting antitumor response resulting in a prolonged disease-free survival...
  40. doi request reprint Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms
    Gert J Ossenkoppele
    Department of Haematology, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
    Br J Haematol 153:421-36. 2011
    ....
  41. ncbi request reprint Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes
    Canan Alhan
    Department of Hematology, VU Institute of Cancer and Immunology V ICI, Cancer Center Amsterdam CCA, VU University Medical Center, Amsterdam, Netherlands
    Cytometry B Clin Cytom 86:207-15. 2014
    ..The aim of this study was to investigate the predictive value of immunophenotyping for response to treatment with azacitidine of Int-2 and high risk MDS patients...
  42. doi request reprint Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS
    Theresia M Westers
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Leuk Res 36:422-30. 2012
    ..Over the years (2005-2011), the concordance between the participating centers increased indicating that the proposed guidelines contributed to a more objective, standardized FC analysis, thereby ratifying the implementation of FC in MDS...
  43. ncbi request reprint Principles of dendritic cell-based immunotherapy in myeloid leukemia
    Theresia M Westers
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Immunobiology 211:663-76. 2006
    ..This review discusses the function and the applicability of leukemia-derived DCs for active specific immunotherapy in myeloid leukemia including possible pitfalls, and describes options to optimize DC-based vaccines...
  44. doi request reprint Human dendritic cell line models for DC differentiation and clinical DC vaccination studies
    Saskia J A M Santegoets
    Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    J Leukoc Biol 84:1364-73. 2008
    ....
  45. ncbi request reprint Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia
    Ilse Houtenbos
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Haematologica 91:348-55. 2006
    ..This review describes ways to improve AML-DC vaccines and discusses critical aspects concerning the development of clinical vaccination protocols...
  46. ncbi request reprint High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
    Martine E D Chamuleau
    Department of Hematology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Haematologica 93:1894-8. 2008
    ..Inhibition of indoleamine 2,3-dioxygenase expressed by myeloid leukemic blasts may result in breaking immune tolerance and offers new therapeutic options for patients with acute myeloid leukemia...
  47. ncbi request reprint Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease
    Otto J Visser
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    BioDrugs 20:201-7. 2006
    ..The encouraging results of RIT in indolent NHL have initiated studies focusing on its benefit for patients with aggressive NHL...
  48. ncbi request reprint Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia
    Theresia M Westers
    Department of Haematology, VU University Medical Centre, De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands
    Cancer Immunol Immunother 52:17-27. 2003
    ....
  49. ncbi request reprint Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010
    Avinash G Dinmohamed
    Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur J Cancer 50:1004-12. 2014
    ..We conducted a nationwide population-based study to assess trends in incidence, initial treatment and survival in MDS patients diagnosed in the Netherlands from 2001 to 2010...
  50. pmc Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells
    Mahban Irandoust
    Department of Pediatric Hematology Oncology, VU University Medical Centre, Amsterdam, The Netherlands
    PLoS ONE 8:e52143. 2013
    ..Although AML cells express SIRPα, its function has not been investigated in these cells. In this study we aimed to determine the role of the SIRPα in acute myeloid leukemia...
  51. doi request reprint Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)
    Gert J Ossenkoppele
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Blood 120:4706-11. 2012
    ..This trial is registered as number NTR904 in The Nederlands Trial Register (www.trialregister.nl)...
  52. doi request reprint Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis
    Gerwin Huls
    Department of Hematology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, The Netherlands
    Blood 116:180-2. 2010
    ..Both patients became transfusion independent, and 1 of the patients attained indeed a complete molecular remission...
  53. ncbi request reprint ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status
    Tom G H Wiggers
    Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands
    Cytometry B Clin Cytom 86:280-7. 2014
    ..In conclusion, ZAP70 expression in CLL cells related to ZAP70 expression in NK cells is a better surrogate marker for mutational status than the conventional T cell related methods...
  54. ncbi request reprint Sequential organ failure predicts mortality of patients with a haematological malignancy needing intensive care
    Alexander D Cornet
    Department of Intensive Care, Institute for Cardiovascular Research, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    Eur J Haematol 74:511-6. 2005
    ..We therefore tried to find predictors of the latter outcomes...
  55. ncbi request reprint Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication?
    Arjan A van de Loosdrecht
    Leuk Res 32:205-7. 2008
  56. ncbi request reprint Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial
    Helga J Droogendijk
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer 107:345-51. 2006
    ..Imatinib mesylate is a potent inhibitor of c-kit receptor tyrosine kinase activity. Therefore, the authors evaluated the efficacy and safety of imatinib mesylate as treatment for patients with systemic mastocytosis...
  57. ncbi request reprint Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists
    Edwin Bremer
    Groningen University Institute for Drug Exploration, Department of Pathology and Laboratory Medicine, University Medical Center Groningen, Groningen, The Netherlands
    Cancer Res 68:597-604. 2008
    ..In conclusion, scFvRit:sFasL efficiently activates CD20 and Fas-apoptotic signaling and may be useful for the elimination of malignant B cells...
  58. doi request reprint Back to basics: in search of the optimal dendritic cell for vaccination in AML
    Willemijn van den Ancker
    Leuk Res 32:1641-3. 2008
  59. ncbi request reprint Divergent autologous T cell responses to leukaemic dendritic cells during remission in acute promyelocytic leukaemia
    Theresia M Westers
    Cell Oncol 27:261-6. 2005